



## Novel Diagnosis and Treatment Approaches in Pancreatic Cancer

Guest Editor:

**Prof. Dr. Atsushi Masamune**

Division of Gastroenterology,  
Graduate School of Medicine  
Sendai, Tohoku University,  
Sendai, Japan

Deadline for manuscript  
submissions:

**31 July 2025**

### Message from the Guest Editor

Dear Colleagues,

Pancreatic cancer still remains intractable due to difficulty in early diagnosis, its rapid progression, and its resistance to conventional therapy. To overcome these difficulties, multidisciplinary approaches including the development of novel diagnosis and treatment approaches are urgently needed. Recently, regarding treatments, the efficacy of neoadjuvant chemotherapy has been proven, drugs that disrupt the tumor–stromal compartment might be useful for improved drug delivery, and targeted agents based on genetic testing such as PARP inhibitors for BRCA pathway-deficient pancreatic cancer and immune checkpoint inhibitors have shown promising results.

In this Special Issue, we will share up-to-date research findings in this field. Articles dealing with a wide range of novel diagnosis and treatment approaches in pancreatic cancer are welcome. Examples include, but are not limited to, the early diagnosis of pancreatic cancer based on risk factors, novel biomarkers, and imaging modalities including artificial intelligence. Basic, translational, and clinical research papers are all welcome.

Prof. Dr. Atsushi Masamune  
Guest Editor





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)